%0 Journal Article
%A Ruf, Theresa
%A Kramer, Rafaela
%A Forschner, Andrea
%A Leiter, Ulrike
%A Meier, Friedegund
%A Reinhardt, Lydia
%A Dücker, Pia
%A Ertl, Carolin
%A Tomsitz, Dirk
%A Tietze, Julia K
%A Gutzmer, Ralf
%A Dabrowski, Evelyn
%A Zimmer, Lisa
%A Gesierich, Anja
%A Zierold, Sarah
%A French, Lars E
%A Eigentler, Thomas
%A Amaral, Teresa
%A Heinzerling, Lucie
%T Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
%J European journal of cancer
%V 203
%@ 0014-2964
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2024-00849
%P 114028
%D 2024
%X Immune checkpoint inhibitors (ICI) induce adverse events (irAEs) that do not respond to steroids, i.e. steroid-refractory (sr) irAEs, and irAEs in which steroids cannot be tapered, i.e. steroid-dependent (sd) irAEs, in about 10
%K Immune checkpoint inhibitors (Other)
%K Immune-related adverse events (Other)
%K Second-line immunosuppressants (Other)
%K Steroid-dependent (Other)
%K Steroid-refractory (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:38652976
%R 10.1016/j.ejca.2024.114028
%U https://inrepo02.dkfz.de/record/289667